

LISTING OF THE CLAIMS

We claim:

1. (Previously presented) A stent comprising a tubular basic body open at its face surfaces, the circumferential wall of which is covered at least in places with a coating system comprising one or more polymer carriers and at least one pharmaceutically active substance, whereby the pharmaceutically active substance, after implantation of the stent into a human or animal body, is released into the surrounding tissue, wherein a concentration of the pharmaceutically active substance varies in the longitudinal direction of the stent so that the pharmaceutically active substance exhibits predetermined locally different elution characteristics in the longitudinal direction of the stent depending on the pathophysiological and/or rheological conditions to be expected of an application.

2. (Previously presented) The stent according to claim 1, wherein the polymer carrier is biodegradable.

3. (Previously presented) The stent according to claim 2, wherein a degradation behaviour of the carrier serves to differentiate the local elution characteristics.

4. (Previously presented) The stent according to claim 1, wherein the concentration of the pharmaceutically active substance is greater adjacent the face surfaces than in a middle portion of the stent.

5. (Previously presented) The stent according to claim 1, comprising a plurality of pharmaceutically active substances, wherein a concentration of a first pharmaceutically active substance is greater adjacent the face surfaces than in a middle portion of the

stent, and wherein a concentration of a second pharmaceutically active substance is greater in a middle portion of the stent than adjacent the face surfaces.

6-8. (Cancelled)

9. (Previously presented) A stent comprising a tubular basic body open at its face surfaces, the circumferential wall of which is covered at least in places with a coating system comprising one or more polymer carriers and at least one pharmaceutically active substance, whereby the pharmaceutically active substance, after implantation of the stent into a human or animal body, is released into the surrounding tissue, wherein a material modification of the at least one carrier varies in the longitudinal direction of the stent so that the pharmaceutically active substance exhibits predetermined locally different elution characteristics in the longitudinal direction of the stent depending on the pathophysiological and/or rheological conditions to be expected of an application.
10. (Previously presented) The stent according to claim 9, wherein the polymer carrier is biodegradable.
11. (Previously presented) The stent according to claim 10, wherein the material modification of the at least one carrier that varies in the longitudinal direction of the stent is the presence of an additive which delays enzymatic breakdown of the polymer carrier.
- 12-14. (Cancelled)